ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

DCT’s Experimental Therapeutic Program Outlined to Board

May 2, 1975

AACI Leaders Regret “Unfortunate Rhetoric,” Pledge Support To Broder

August 11, 1989

ASCO Members asked To Help In Planning

August 26, 1988

Doctor’s Allegation Of Drug Safety Problem Starts Controversy With Manufacturer

May 5, 1995

Institute Of Medicine Report Says Insurers Should Pay Patient Care Costs In Clinical Trials

February 24, 1989

Chi Van Dang Named Director of University Of Pennsylvania Abramson Cancer Center

July 15, 2011